Zenas BioPharma, Inc. (ZBIO) stock analysis
In our weekly check, Zenas BioPharma, Inc. is graded D (A to F). Of 19 checks on debt, profit, cash flow and trend: 7 pass, warnings: 2, red flags: 10.
About Zenas BioPharma, Inc.
Zenas BioPharma, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as ZBIO.
What our checks show for ZBIO
Red flags
- Debt is high against equity (1.42x). That limits room in a downturn.
- The company has an operating loss, so it does not cover the interest bill: interest is paid from cash or new debt.
- Weak EPS forecast
- Weak EPS growth
- The company is losing money.
- Free cash flow is negative: the business spends more cash than it brings in.
- The price swings a lot: 134% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 75% from a peak. Would you have held through that?
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- A small company (market value $1.9 billion): usually riskier and followed by fewer analysts.
- The share count grew by 16.7% in 2 years: each shareholder owns a smaller slice.
Strengths
- Analysts expect revenue to grow about 226% a year over the next years.
- Analysts expect the net margin to improve by 4812 points from today's -4926%.
- Beta -1.02: the stock usually moves less than the market.
Similar companies
AGIO · FTRE · MAZE · TRVI · BCRX
Questions
What grade does Zenas BioPharma, Inc. (ZBIO) have?
In our weekly check, Zenas BioPharma, Inc. is graded D (A to F). Of 19 checks on debt, profit, cash flow and trend: 7 pass, warnings: 2, red flags: 10. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of ZBIO stock?
This week's biggest flags for Zenas BioPharma, Inc.: High debt, Weak interest cover, Weak EPS forecast. In total 12 of 19 checks show a warning or a red flag.
What does Zenas BioPharma, Inc. do?
Zenas BioPharma, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as ZBIO.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis